GEN-MKT-18-7897-A
Nov 7, 2019 | Blogs, Technology | 0 comments
Would you like to take your LC-MS/MS analysis from 0 to 3 mL/min without the complexity of changing probes or splitting the LC flow? Then take a look into the Turbo V ion source from SCIEX.
Introduced more than 15 years ago, the Turbo V ion source continues to be a gold standard for rugged and user-friendly source design, for both ESI and APCI ionization. This shrewd architecture provides outstanding robustness and sensitivity when analyzing complex biological matrices with minimal maintenance. By merging two orthogonal streams of hot gas in the ESI region, efficient desolvation and hydrodynamic focusing of ions towards the sampling orifice is achieved.
For higher flow rate applications, this can translate to boosts in sensitivity of several orders of magnitude over unheated ESI sources. Desolvation is greatly improved without disrupting the curtain gas flow and greatly boosts the robustness of the entire system. Figure 1 schematically represents the heated gas flows within the Turbo V source.
The success of the Turbo V ion source over the years served as the inspiration and foundation upon which the more recently introduced IonDrive Turbo V and OptiFlow Turbo V ion sources are designed. Each of these sources benefits from the use of orthogonally placed jets of heated gas directed at the liquid sample spray to enable even more efficiency of desolvation at different liquid flow regimes. While robustness and ruggedness were built in from the start, plug-and-play simplicity and a “just put it on, and it works” engineering is typical of all present-day SCIEX sources based on the Turbo V. Figure 2 highlights the wider heaters involved with the IonDrive Turbo V design for increased desolvation and thus higher sensitivity. The red square indicates the ‘sweet spot’ of standard Turbo V and the blue square highlights the bigger ‘sweet spot’ of IonDrive.
Key benefits of the IonDrive Turbo V Source
The recent introduction of OptiFlow technology allows the use of the Turbo V design to be translated to lower flow rate chromatography, such as nano and micro-flow rates. The benefit of lower flows can help with gains in sensitivity especially when you are ‘sample limited’. Significant research was done to develop a low-flow source that is sensitive while maintaining high robustness and ease of use of higher-flow sources. The result is an ion source, based on the legendary Turbo V design, with the ability to switch easily between nano and microflow regimes. No need to change the source, break vacuum and the system can be back up and running in minutes. Simple, robust and reliable. Figure 3 shows a picture of the Optiflow ion source based on the Turbo V geometry. Learn more about the legendary Turbo V ion source >
To see more about the 50 years of SCIEX mass spectrometry technology innovations visit the Generation Quant docu-series.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
Posted by
You must be logged in to post a comment.
Share this post with your network